Engflag

Dologel-CT

Quick links to important sections

Dologel-CT

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dologel-CT

Property Description
Active Ingredients Choline Salicylate, Cetalkonium Chloride
Form Oromucosal Gel Preparation
Pharmacological Class Topical NSAID and Local Antiseptic
Common Use Symptomatic relief for minor oral irritations
Origin Synthetic Combination Formulation

Defining Dologel-CT: Class and Form

Dologel-CT is classified as a Combination Drug Formulation delivered as an Oromucosal Gel Preparation designed for localized action on the soft tissues of the mouth. Its core identity is rooted in its primary active component, Choline Salicylate, which belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The preparation is a synthetic formulation presented as a gel, which allows it to adhere well to the moist mucosal lining, a feature that distinguishes it from non-mucoadhesive liquid oral treatments. This specific form ensures the active components maintain prolonged contact at the affected site.

What are the Active Ingredients in Dologel-CT?

The therapeutic function of Dologel-CT is derived from the combination of its two distinct Active Pharmaceutical Ingredients (APIs): Choline Salicylate and Cetalkonium Chloride. Choline Salicylate provides the local analgesic and anti-inflammatory action by modulating inflammatory signals at the site of application. The secondary API, Cetalkonium Chloride, functions as a fast-acting local antiseptic agent, aiming to reduce the presence of microorganisms (like bacteria) on the irritated mucosal surface. This specific dual composition targets both discomfort and potential microbial involvement simultaneously, providing integrated support.

General Purpose of this Dual-Action Gel

The general purpose of Dologel-CT is to provide rapid, localized integrated therapeutic support for minor irritations within the oral cavity, such as those caused by minor abrasions. By combining an analgesic and an antiseptic in one product, the formulation simultaneously works to lessen the sensation of pain and inflammation while contributing to a clean oral surface environment. This dual-action mechanism provides foundational symptomatic relief localized to the area of application.

What side effects are possible with Dologel-CT?

Official Safety Profile and Adverse Reactions

The safety profile of Dologel-CT, an oromucosal gel containing Choline Salicylate and Cetalkonium Chloride, is primarily defined by the officially documented risks associated with topical salicylate exposure.

Most reported adverse reactions are classified as Not known frequency, meaning the rate cannot be estimated from available data, and are generally localized effects at the site of application.

Adverse Reactions by System-Organ Class

The most frequently expected effects are classified under General Disorders and Administration Site Conditions, which include a transient burning or stinging sensation that may occur upon application. Other effects documented in official labeling include Hypersensitivity reactions (Immune System Disorders), Paraesthesia (Nervous System Disorders), and instances of Stomatitis (Gastrointestinal Disorders).

Serious Safety Considerations

The gel's safety profile includes documentation of rare but serious potential reactions. The salicylate content carries a high-level theoretical risk of Reye's Syndrome and severe hypersensitivity reactions, such as bronchospasm and asthma, particularly in susceptible patients. These risks dictate specific safety limitations.

Population-Specific Restrictions

Official regulatory documents mandate specific usage restrictions. Dologel-CT is contraindicated in children and adolescents under 16 years of age when they are experiencing viral illnesses (e.g., influenza or varicella). This is a required safety measure to mitigate the established risk of Reye's Syndrome linked to systemic salicylate absorption. The medicine is also contraindicated for patients with known hypersensitivity to salicylates, other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), or the active ingredients.

Overdose and Emergency Response

The official regulatory profile for Dologel-CT overdose centers on the systemic toxicity risk associated with its salicylate component following accidental ingestion or excessive topical use. Documented initial overdose presentations, collectively known as salicylism, commonly involve a cluster of sensory and gastrointestinal symptoms. These manifestations include tinnitus (ringing in the ears), hearing impairment, nausea, vomiting, headache, and confusion, as documented in regulatory information.

Overdose is classified as having the potential for life-threatening systemic outcomes. These severe manifestations involve critical acid-base and electrolyte disturbances, such as severe metabolic acidosis, as well as neurological effects like convulsions and coma. Acute organ damage, including pulmonary oedema and acute renal failure, are also stated risks.

In any suspected or known overdose situation, regulatory guidance explicitly states to seek immediate medical attention or contact emergency services without delay. Due to the risk of rapid deterioration, hospital monitoring is required. Management involves symptomatic and supportive treatment and the correction of fluid imbalances. No specific antidote is known for this toxicity; therefore, treatment may involve procedures like enhanced elimination measures or the use of activated charcoal, as described in official prescribing information. Regulatory documents also note that children and infants may have a heightened susceptibility to severe toxicity, particularly the development of severe metabolic acidosis.

Therapeutic Uses of Dologel-CT

Dologel-CT is commonly used across conditions characterized by periods of heightened symptoms in the oral cavity. The formulation is primarily relevant for easing localized pain and soreness. The product is applied in scenarios where additional management of discomfort is required for conditions involving sore spots from dentures, orthodontic appliance irritation, and common mouth ulcers (canker sores).

This topical support is used to provide symptomatic relief for localized pain and tenderness arising from minor irritations of the oral soft tissues. It helps address symptom clusters like acute discomfort and painful sensitivity, providing support that contributes to easing discomfort during periods of heightened symptoms.

“The gel is commonly used in situations involving recurrent or episodic manifestations of minor oral discomfort.”

Quick Fact: Relief for Localized Oral Discomfort

Dologel-CT is applied to manage minor inflammation, targeting symptom groups such as redness, mild swelling, and the associated burning sensation. Its combination of ingredients may assist with maintaining functional stability during symptomatic periods and contributes to easing the overall symptom load.

Regulatory References

  1. NAFDAC Summary of Product Characteristics (SmPC) for Mouth Gel

Eligibility and Restrictions for Use

Who Can and Cannot Use Dologel-CT?

The eligibility for Dologel-CT, an oromucosal gel containing Choline Salicylate and Cetalkonium Chloride, is strictly determined by official regulatory criteria, primarily due to the salicylate component.

Official Eligibility Summary

Classification Population/Condition
Allowed Use Adults and adolescents aged 16 years and older
Absolute Contraindication Children and adolescents under 16 years of age
Contraindicated Conditions Known salicylate hypersensitivity, active peptic ulceration, salicylate-sensitive asthma

Restrictions and Special Considerations

Age and Absolute Contraindication: The medicine is formally contraindicated in patients under 16 years old. This minimum age threshold is mandated due to the risk of Reye's Syndrome associated with salicylate use in this age group, especially during viral illness.

Comorbidity and Organ Function: Use is prohibited in individuals with a history of active peptic ulceration or salicylate-sensitive asthma.

Pregnancy and Lactation: Official labeling states that use during pregnancy and breastfeeding is generally not recommended. Furthermore, use should be restricted in patients with severe renal or hepatic impairment as their ability to clear the absorbed salicylate may be compromised.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Dologel-CT is based on the systemic effects of its active salicylate component, Choline Salicylate, even when applied as a topical oromucosal gel. The regulatory documentation establishes specific constraints regarding co-administration with other medicines and substances.

Formal Interaction Restrictions

Co-use of Dologel-CT is formally restricted with Acetylsalicylic Acid (Aspirin) and other salicylates. The regulatory guidance states that these combinations should not be used except under specific medical direction, reflecting a constraint against the cumulative exposure to salicylates.

Documented Pharmacodynamic and Exposure Effects

The salicylate component is documented to modify the pharmacological action and exposure of certain co-administered medicinal products, which classifies these as clinically significant interactions:

  • Anticoagulants (e.g., Warfarin): The salicylate may enhance the effect of anticoagulants, potentially increasing the risk of adverse outcomes related to blood thinning.
  • Uricosurics (e.g., Probenecid): The salicylate may inhibit the action of uricosurics, which diminishes the efficacy of the co-administered medicine.
  • Methotrexate: The salicylate component may increase the serum concentration of Methotrexate.

Substance Interaction

Ethanol (Alcohol) is listed as a substance to be avoided during co-use. Regulatory warnings advise against combining Dologel-CT with alcohol due to the potential for enhanced gastrointestinal adverse effects associated with the salicylate.

Mechanism of Action

The mechanism of Dologel-CT's local activity is defined by the complementary action of two distinct mechanistic domains: the suppression of biochemical inflammatory signals and the physical disruption of microbial surface structures.

Modulating Local Inflammatory Mediator Synthesis

The Choline Salicylate component achieves its effect through the inhibition of the Cyclo-oxygenase (COX) enzyme system. By blocking this enzyme, the drug suppresses the local production of prostaglandins and other eicosanoids, which are potent biochemical signals that initiate inflammation and nociceptive input. This mechanism acts directly on the Arachidonic Acid Cascade to modulate the intensity of the localized inflammatory response. The resulting physiological effect is a reduction of local vascular changes and a decrease in peripheral nociceptor sensitization.

Destabilizing Microbial Structural Integrity

The supportive component, Cetalkonium Chloride, functions as a cationic surfactant. It engages a purely physical mechanism by binding to and disrupting the lipid and protein components of microbial cell membranes on the mucosal surface. This interaction breaches the microbe's structural barrier, causing leakage of internal contents and cell death. This process limits microbial proliferation, preventing the microbial contribution to sustained physiological disturbances.

Dosage and Administration Information

How to Use Dologel-CT Gel: Official Administration Guidelines

This section outlines instructions for the proper use of Dologel-CT, based on prescribing information.

Administration Details

Dologel-CT is a gel formulated for local topical application solely to the oral mucosa (e.g., gums, inner cheeks). It is strictly for external use within the mouth and must not be swallowed voluntarily.

Guideline Instruction
Dosing Schedule Apply a small, pea-sized amount of the gel (approximately half an inch) directly to the affected area.
Frequency Apply typically 3 to 4 times a day, maintaining a minimum interval between applications (e.g., not more than once every 3 hours).
Age Constraint Not recommended for use in children and adolescents under 16 years of age.
Meal Timing To maximize adherence, avoid eating or drinking for at least 30 minutes after application.

Procedural Steps

  1. Preparation: Wash hands thoroughly before use. For best adherence, gently dry the affected area of the oral mucosa.
  2. Application: Apply the small, pea-sized dose to a clean fingertip or cotton swab, then gently massage the gel onto the sore area.
  3. Post-Application: Wash hands thoroughly after application. Maintain the waiting period before consuming food or liquid.

Protocol Summary

The official administration protocol mandates a localized application technique using a measured dose to specific oral surfaces. The key constraints are the mandatory minimum age of 16 and the requirement to avoid ingestion and consumption of food/drink immediately following use. This structured approach ensures standardized delivery of the topical formulation.

Recent Clinical Evidence

Dologel-CT is a topical preparation containing a combination of active ingredients typically including Choline Salicylate, Lidocaine (also known as Lignocaine), and Benzalkonium Chloride (or similar antiseptic). Clinical evidence for the use of this combination gel focuses on its ability to manage localized oral discomfort.

Evidence for Component Activity

The gel's function relies on the established properties of its individual components, which are summarized in clinical studies and authoritative pharmaceutical texts:

  • Lidocaine (Analgesic): This component is a local anesthetic. Studies, including randomized trials of topical oral lidocaine, show that it is designed to provide rapid, localized pain relief by temporarily blocking nerve signals in the area of application. The efficacy in managing symptoms like pain from oral ulcers or dental irritation is primarily attributed to this numbing effect.

  • Choline Salicylate (Anti-inflammatory): This compound is a non-steroidal anti-inflammatory drug (NSAID) derivative. Research indicates that salicylates inhibit the production of substances in the body that contribute to inflammation and swelling. Applied topically, this may assist in reducing localized inflammation associated with oral lesions.

  • Benzalkonium Chloride (Antiseptic): This agent is an antiseptic and disinfectant. Its inclusion is supported by evidence demonstrating its bactericidal and fungicidal properties, which work to prevent the development of secondary bacterial or fungal infections in compromised oral tissues, such as those with open ulcers or sores. Clinical utility is recognized for minimizing risk of infection in the application area.

Summary of Therapeutic Focus

The combination of these ingredients is studied for the short-term, localized management of symptoms associated with mouth ulcers (canker sores), gingivitis, denture irritation, and minor oral lesions. Clinical use is typically confined to the temporary relief of pain and discomfort at the site of application. The use of salicylate-containing gels in children and adolescents requires professional caution due to general safety considerations for this class of compounds.

Frequently Asked Questions (FAQ)

Common questions about Dologel-CT (FAQ)

Q: What should I do if I accidentally swallow a large amount of the gel?

If a large amount of Dologel-CT is accidentally swallowed, or if symptoms of salicylate toxicity (such as dizziness, ringing in the ears, or changes in hearing) occur, official guidance suggests that you contact a healthcare professional or seek emergency medical care. The product is intended only for topical use in the mouth.

Q: Can I use Dologel-CT on skin or on lips (outside the mouth)?

The official product information specifies that Dologel-CT is formulated for topical application only to the oral mucosa (the soft tissues inside the mouth). It is not indicated for use on external skin or lips, as this is not the approved route of administration.

Q: What is the exact dose amount to be applied each time?

Regulatory guidelines describe the dose amount in physical terms, specifying the application of a 'small, pea-sized amount' or 'approximately half an inch' of the gel directly to the affected area. The exact weight in milligrams (mg) or volume in milliliters (mL) is not typically provided on the patient-facing label.

Q: How long does it take for Dologel-CT to start working for pain relief?

Official product information suggests the gel's Lidocaine component, a local anesthetic, is designed to provide localized pain relief at the application site. While the speed of the numbing effect is not precisely documented, the anti-inflammatory component has a documented onset of action within 1–2 hours after absorption.

Q: Is Dologel-CT safe to use while pregnant or breastfeeding?

Official labeling states that use of Dologel-CT is generally not recommended during pregnancy. Similarly, caution is advised while breastfeeding, as low quantities of salicylates are known to pass into breast milk. Official guidance indicates you should consult a doctor before using this medicine if you are pregnant or breastfeeding.

Q: Does Dologel-CT treat the cause of the ulcer or just the pain?

The product is officially indicated for the symptomatic relief of pain and discomfort associated with minor oral irritations and ulcers. It works by combining an anti-inflammatory and pain reliever with an antiseptic agent, which may help reduce the presence of micro-organisms, but it is primarily a localized management for symptoms.

How should Dologel-CT be stored and disposed of?

How to Store and Dispose of Dologel-CT Gel

Official regulatory guidelines strictly define the storage and disposal of Dologel-CT to maintain product integrity and ensure safety.

Required Storage Conditions

Condition Requirement
Temperature Store below 30°C. Do not freeze.
Protection Keep in a clean, dry place, protected from light.
Container Must be kept in the original container and tightly closed.

Stability and Safety

The gel must not be used after the expiry date has passed. For safety, it is required to store the medicine out of the sight and reach of children and pets at all times.

Disposal of Unused Product

Unused or expired Dologel-CT must be disposed of safely according to labeled instructions and local regulations. Disposal procedures must ensure the product is not consumed by others. Medicines not on the FDA's flush list should be mixed with an unappealing substance, sealed in a bag, and thrown into the household trash, or returned to a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dologel-CT found in:

A-Z Index: